Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medtronic plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medtronic plc's regulatory disclosures and financial reporting.
Medtronic plc reports that Chief Accounting Officer Denise L. Blomquist received new equity awards and had shares withheld for taxes. On August 3, 2026 she was granted 2,337 restricted stock units vesting 100% on the third anniversary of grant, 2,337 performance share units where each unit is a contingent right to one share with performance conditions measured on April 27, 2029 over a three-year performance period (issuing 2,337 shares at target performance, up to 5,609 at maximum, and possibly 0 if minimum metrics are not met), and 1,366 stock options exercisable at $86.68 per share, vesting 25% per year and expiring August 3, 2036. On July 31, 2026, 212 shares were withheld at $85.39 per share to pay taxes on previously vested restricted stock units, and her reported holdings include 136 shares acquired through dividend reinvestment since the prior report.
Medtronic plc reported insider equity activity by SVP, Chief HR Officer Walter Matthew R. On 2026-08-03 he received 5,769 restricted stock units that vest 100% on the third anniversary of grant, 14,421 performance share units that can settle for between 0 and 34,610 shares based on performance metrics over a three-year period with conditions measured through April 27, 2029, and stock options on 40,973 ordinary shares at 86.6800 per share expiring 2036-08-03, which become exercisable 25% per year beginning one year after grant. On 2026-07-31, 1,675 ordinary shares were withheld at 85.3900 per share to satisfy tax obligations upon vesting of previously reported restricted stock units.
Medtronic EVP & President, Neuroscience Thompson Kweli received equity compensation awards, including 17,306 performance share units, 49,167 stock options with a strike price of $86.68 expiring in 2036, and 6,923 restricted stock units vesting after three years. Separately, 1,739 shares were withheld to satisfy taxes on previously vested RSUs.
Medtronic plc reported that EVP, GC and Secretary Michelle Quinn received multiple equity awards on 2026-08-03. She was granted 6,346 restricted stock units that vest in full on the third anniversary of grant and now holds 26,721 ordinary shares directly. She also received 15,863 performance share units, which can result in between 0 and 38,071 ordinary shares based on performance through April 27, 2029, and 45,070 stock options with an exercise price of 86.6800 per share, vesting 25% annually and expiring on August 3, 2036.
Medtronic EVP & Chief Financial Officer Thierry Pieton reported equity awards dated August 3, 2026, including 11,537 restricted ordinary shares, 28,842 performance share units tied to three-year performance goals, and 81,945 stock options with an $86.68 exercise price expiring in 2036.
Medtronic plc reported insider equity activity for EVP Michael Marinaro. On July 31, 2026, 3,356 ordinary shares were withheld at $85.39 per share to satisfy tax liabilities on previously vested restricted stock units. On August 3, 2026, he received grants of 10,960 and 46,147 restricted stock units with multi‑year vesting, 27,400 performance share units that can yield up to 65,760 shares based on performance, and 77,848 stock options exercisable at $86.68 per share expiring in 2036.
Medtronic plc EVP & President Cardiovascular Harry Skip Kiil received several equity awards. On August 3, 2026 he was granted 23,074 performance share units that may result in between 0 and 55,378 shares depending on three-year performance measured through April 27, 2029, 65,556 stock options with an $86.68 exercise price expiring in 2036, and 9,230 restricted stock units that vest fully on the third anniversary of grant.
On July 31, 2026, 3,074 ordinary shares were withheld at $85.39 per share to satisfy tax obligations upon the vesting of previously granted restricted stock units.
Medtronic Chairman and CEO Geoffrey Martha reported multiple equity awards. On August 3, 2026 he received 103,831 Performance Share Units, 41,533 restricted stock units, and two stock option grants for 295,002 and 273,150 shares at $86.6800 per share, with options vesting 25% annually and expiring August 3, 2036. PSU payouts can range from 0 to 249,194 shares based on performance through April 27, 2029. On July 31, 2026, 15,810 shares were withheld to cover taxes on previously vested restricted stock units.
Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported a Form 4 transaction where 2,069 Ordinary Shares were withheld to pay taxes upon the vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 20,375 Ordinary Shares, including 697 acquired through dividend reinvestment.
Medtronic plc senior vice president and chief HR officer Walter Matthew R. completed an open-market sale of 3,102 Ordinary Shares of Medtronic on July 8, 2026 at a price of $83.15 per share.
After this transaction, he directly owns 35,694 Ordinary Shares, so the sale represents a relatively small portion of his overall holdings. His reported holdings also include 107 shares acquired through Medtronic’s Employee Stock Ownership Plan since his prior report.